Y Intercept Hong Kong Ltd Acquires Shares of 6,781 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Y Intercept Hong Kong Ltd bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,781 shares of the specialty pharmaceutical company’s stock, valued at approximately $405,000.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Pacer Advisors Inc. boosted its holdings in ANI Pharmaceuticals by 23,259.8% in the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after buying an additional 565,910 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of ANI Pharmaceuticals in the third quarter worth approximately $13,043,000. Millennium Management LLC raised its stake in ANI Pharmaceuticals by 1,005.8% in the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after purchasing an additional 209,272 shares during the last quarter. Mizuho Markets Americas LLC acquired a new position in ANI Pharmaceuticals in the 3rd quarter valued at $11,670,000. Finally, Assenagon Asset Management S.A. lifted its holdings in ANI Pharmaceuticals by 149.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company’s stock valued at $11,107,000 after purchasing an additional 111,613 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Buying and Selling

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,731 shares of company stock valued at $2,015,861. Company insiders own 12.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ANIP. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Piper Sandler started coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $56.36 on Tuesday. ANI Pharmaceuticals, Inc. has a 52 week low of $51.88 and a 52 week high of $70.81. The stock’s fifty day moving average is $58.02 and its two-hundred day moving average is $60.24. The company has a market capitalization of $1.19 billion, a P/E ratio of -102.47 and a beta of 0.73. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the prior year, the company posted $1.05 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 12.5% compared to the same quarter last year. Equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.